• CHF 2.6 Million raised from private investor
• Dr Anthony Wild and Dr Matthias Staehelin to join board of directors

Swiss Nuclides AG, a developer of novel radionuclide PET tracers for the precision diagnostics, today announces the first closing of its Series A financing. The Company has raised CHF 2.6 million from private investors with Turos Capital AG. The proceeds will be used to continue the preclinical and clinical develop of its lead molecules for prostate cancer, neuroendocrine tumours, and immunotherapy selection. Swiss Nuclides is developing the PET tracers on a novel radionuclide production platform which enables the broad availability of these tracers while keeping the radiation burden on the patient to a minimum. Dr Anthony Wild and Dr Mathias Staehelin will join the board of directors of Swiss Nuclides.  

Dr. Leila Jaafar-Thiel, CEO and Founder comments: “We welcome the new investors to Swiss Nuclides. The rapidly growing field of radiotherapeutics highlights the unmet clinical need for a broader portfolio of radiodiagnostic PET tracers alongside. Precision radiotherapeutics has shown astounding efficacy in some cancer indications like prostate cancer and neuroendocrine tumours. Swiss Nuclides is working towards a future in which all patients have access to an affordable and effective personalised treatment.

Dr Anthony Wild added: “I am excited to invest in a company that is on the cutting edge in the development of novel radionuclides for cancer diagnostics. I look forward to supporting Leila Jaafar-Thiel and her outstanding team at Swiss Nuclides in developing their potentially disruptive technology and thereby improving patients’ prognoses and chances of survival.”

About Swiss Nuclides AG: developing, producing and selling innovative PET tracers for personalized cancer diagnostics and staging of different types of cancer, so that radiologists can select the best PET tracer molecule that is appropriate for the patient and their cancer indication. We strive to develop precision diagnostic tools for cancer that are better, safe, more affordable and can be made available for every cancer patient.

For any media contacts: info@swissnuclides.ch or nikolai.ahrens@turoscapital.com

Aarau, June 1st, 2021

Categories: Milestones

Scroll Up